表紙
市場調査レポート

皮下用生物製剤市場

Subcutaneous Biologics Market, 2015 - 2025

発行 ROOTS ANALYSIS 商品コード 322757
出版日 ページ情報 英文 219 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
皮下用生物製剤市場 Subcutaneous Biologics Market, 2015 - 2025
出版日: 2015年01月12日 ページ情報: 英文 219 Pages
概要

皮下投与は他の投与ルートに勝る多くの利点があります。時間短縮や医療費の削減、治療適合性の向上などです。皮下用生物製剤市場は今後10年間、CAGR7.0%で拡大すると予測されています。皮下投与の利点と自己注入薬剤の拡大動向などが同市場を牽引しています。

当レポートでは、急速に拡大する皮下用生物製剤市場について広範に調査し、上市済み薬剤の動向、市場の規模と将来動向、技術開発業者のプロファイルなどをまとめています。

第1章 序論

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • 概要と背景
  • 治療薬の不安定性
  • 皮下投与

第4章 皮下用生物製剤市場

  • 本章の概要
  • 生物製剤:概要
  • 生物製剤の皮下投与:新興の動向
  • 市場における皮下用生物製剤
  • ケーススタディ

第5章 皮下用生物製剤技術

  • 本章の概要
  • 技術プロファイル

第6章 生物製剤の皮下投与のためのドラッグデリバリーシステム

  • 本章の概要
  • 皮下デリバリーシステムの種類
  • 適切なデリバリー装置の選択
  • ウェアラブルインジェクター
  • プレフィルシリンジ
  • オートインジェクター
  • セリフインジェクターの安全性
  • 薬剤再構成デリバリーシステム
  • ニードルフリーインジェクター

第7章 市場規模と予測

  • 本章の概要
  • 皮下用生物製剤市場
  • ドラッグデリバリーシステム市場
  • 技術ライセンシング支払

第8章 ケーススタディ:技術開発業者

  • 本章の概要

第9章 SWOT分析

第10章 インタビュー原稿

第11章 結論

第12章 付録1:表データ

第13章 付録2:企業・組織リスト

図表

目次
Product Code: RA10030

Amongst various efforts to ensure efficient drug delivery, subcutaneous administration has emerged as one of the most promising approaches to deliver viscous biologic drugs in a patient friendly format. Owing to its numerous compelling advantages, the concept has gained huge traction in recent years. The flexibility and convenience of subcutaneous administration over other routes of delivery, along with the increasing trend of self-medication, are some of the key factors contributing to the expansion of this market.In addition, the plethora of self-administration devices created by device manufacturers to fulfil the demand for subcutaneous delivery systems is acting as a key enabler. Examples of such devices include prefilled syringes, auto-injectors, needle free injectors and bolus-injectors.

The market is characterized by the presence of a robust pipeline comprising various large molecules; these include proteins, peptides and antibodies in different phases of development being investigated for their subcutaneous use. Furthermore, the approved therapeutic products that are currently delivered intravenously are being developed as subcutaneous formulations to enhance their use and adoption.The upcoming trend is likely to create a positive impact on healthcare productivity and therapy adherence.

Though the market for biologics is considerably mature (with majority of existing biologic therapies being given intravenously), subcutaneous formulation and administration presents new opportunities for multiple stakeholders in the market.Providing a subcutaneous formulation of a particular drug in self-injectable format also helps a pharmaceutical company in achieving brand differentiation for that therapy against competitors within the same therapeutic category.

Synopsis:

The ‘Subcutaneous Biologics: Products, Technologies and Delivery Systems' report provides an extensive study of the rapidly growing market of subcutaneous biologic drugs. It is an emerging area that is gaining substantial attention from researchers and manufacturers across the globe. Subcutaneous delivery provides numerous advantages over other routes of delivery. Some of the major benefits include reduction in time spent in drug administration, reduced patient time at healthcare facilities, decreased healthcare costs and improved therapy compliance.The utility of viscous biologics in the treatment of chronic diseases, the increasing trend of self-medication and requirement of high concentration subcutaneous formulation of biologics are some of the driving factors behind the market's evolution.

The study not only provides an in-depth analysis of pipeline and marketed subcutaneous biologic drug candidates but also includes a detailed discussion on the formulation and delivery aspects associated with such biological macromolecules. In addition, the advancing trend of transition from intravenous to subcutaneous and the fundamental challenge of formulation of biologics into subcutaneous format highlight the crucial role of technology developers in this field. The requirement of suitable delivery systems for subcutaneous administration also presents immense growth prospects for device manufacturing firms which are working aggressively to provide a diverse range of self-injection devices.

In fact, one of the key objectives of the report is to identify the future potential of the industry for these stakeholders. In addition to the market forecast for subcutaneous biologic drugs, we have also provided a ten year forecast of the subcutaneous delivery systems including prefilled syringes, drug reconstitution systems and bolus injectors. The base year for the report is 2014. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from primary and secondary research.

Example Highlights

  • 1. Pharmaceutical giants,such as Roche,are involved in development of subcutaneous formulations for their approved therapies in order to enhance their use and adoption. Herceptin SC and MabThera SC represent some of the successful examples of this novel approach.
  • 2. With formulation being a crucial aspect, technology developers have carved an important role for themselves in the market. During our research, we identified nine such companies which are involved in development and commercialization of technologies to form stable subcutaneous formulations of proteins, peptides, antibodies and other large molecules. Halozyme is a pertinent example; the company has entered into numerous deals with big pharmaceutical firms to develop subcutaneous formulations for their products.
  • 3. The pipeline of subcutaneous biologics represents one of the underlying drivers of the market. In addition to the 55 marketed subcutaneous biologics, there are 196other such molecules in clinical development. Though biologics are being developed targeting numerous diseases across the therapeutic spectrum;inflammatory and metabolic disorders are amongst the prime focus areas.
  • 4. We expect the overall market of subcutaneous biologics to grow at a CAGR of 7.0% over the next decade; factors such as the advantages of subcutaneous administration and the growing trend for self-injection medications will drive this uptake.
  • 5. In terms of delivery systems, we expect the annual market for prefilled syringes, novel drug reconstitution systems and bolus injectors for subcutaneous administration of biologics to be worth USD 1.4 billion, USD 0.9 billion and USD 8.1 billion respectively by 2025.
  • 6. The technology developers stand to benefit from technology licensing deals; these generally present strong financial incentives to the licensors in the form of upfront payments (USD 8 - 20 million) and milestone payments (USD 100 - 300 million).

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of subcutaneous biologics market.

Chapter 3 provides a general introduction on the subcutaneous route of administration, including its advantages and limitations. We have also covered, in detail, the concept of stabilization and formulation associated with subcutaneous administration of biological macromolecules.

Chapter 4 analyses the global subcutaneous biologics market. This chapter identifies the various marketed and pipeline candidates. In addition to the case studies of some of the leading subcutaneous biologics, the chapter provides an in-depth analysis of pipeline by phase of development.

Chapter 5 focuses on the formulation technologies that enable subcutaneous administration of biologic drugs. Each technology profile covers various aspects including technology description, advantages, drugs using the technology and related developments.

Chapter 6 provides details on the drug delivery systems available in the market that facilitate subcutaneous delivery of biologics.

Chapter 7 includes profiles of key technology developers in the subcutaneous biologics market. Each company profile includes information such as financial performance, pipeline overview, technology overview, recent developments and future outlook.

Chapter 8 presents a detailed ten year forecast for the subcutaneous biologics market and drug delivery systems. Due to the uncertainty surrounding some of the key assumptions, we have presented three different growth tracks outlined as conservative, base and optimistic scenarios.The chapter also provides a view on financial terms and conditions involved in technology licensing deals identified from various spheres of the pharmaceutical industry.

Chapter 9 provides the SWOT analysis of the subcutaneous biologics market giving strategic insights to the major factors that are likely to drive future growth while also highlighting the weaknesses and threats that can negatively impact the industry's evolution.

Chapter 10 is a collection of transcripts of interviews conducted during the course of this study.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix which provides a list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Instability in Therapeutic Products
  • 3.3. Subcutaneous Administration
    • 3.3.1. Formulation for Subcutaneous Drug Delivery
    • 3.3.2. Method of Subcutaneous Administration
    • 3.3.3. Advantages of Subcutaneous Route of Administration
    • 3.3.4. Limitations of Subcutaneous Administration
    • 3.3.5. Challenges in Subcutaneous Formulation

4. SUBCUTANEOUS BIOLOGICS MARKET

  • 4.1. Chapter Overview
  • 4.2. Biologics: An Overview
  • 4.3. Subcutaneous Administration of Biologics: An Emerging Trend
  • 4.4. Subcutaneous Biologics in the Market
  • 4.5. Case Studies
    • 4.5.1. Herceptin (Genentech/Roche; Chugai)
      • 4.5.1.1. Background and History of Development
      • 4.5.1.2. Indications and Dosage Forms
      • 4.5.1.3. Target Population
      • 4.5.1.4. Sales, 1999 - 2013
      • 4.5.1.5. Launch of Subcutaneous Formulation
      • 4.5.1.6. ENHANZE™: The Technology behind Subcutaneous Formulation of Herceptin (Halozyme Therapeutics)
      • 4.5.1.7. Advantages of Subcutaneous Herceptin over Intravenous
      • 4.5.1.8. Herceptin Likely to be the First Biologic to be Launched in Bolus Injector
    • 4.5.2. MabThera/Rituxan/Zytux (Biogen Idec; Genentech/Roche; Chugai)
      • 4.5.2.1. Background and History of Development
      • 4.5.2.2. Indications and Dosage Forms
      • 4.5.2.3. Target Population
      • 4.5.2.4. Sales, 1999 - 2013
      • 4.5.2.5. Launch of MabThera Subcutaneous
      • 4.5.2.6. Advantages of Subcutaneous MabThera over Intravenous
    • 4.5.3. Neulasta (Amgen)
      • 4.5.3.1. Background and History of Development
      • 4.5.3.2. Indications and Dosage Forms
      • 4.5.3.3. Launch in Prefilled Syringe
      • 4.5.3.4. Sales, 2003-2013
    • 4.5.4. Humira (AbbVie; Eisai)
      • 4.5.4.1. Background and History of Development
      • 4.5.4.2. Indications and Dosage Forms
      • 4.5.4.3. Launch in Prefilled Syringe
      • 4.5.4.4. Sales, 2003 - 2013
    • 4.5.5. Enbrel (Amgen; Pfizer; Takeda)
      • 4.5.5.1. Indications and Dosage Forms
      • 4.5.5.2. Move from Vial to Syringes
      • 4.5.5.3. Sales, 2002 - 2013
    • 4.5.6. Leading Subcutaneous Biologics (By Sales), 2013
  • 4.6. Subcutaneous Drugs in Pipeline
    • 4.6.1. Pipeline Analysis
      • 4.6.1.1. Distribution by Type of Molecule
      • 4.6.1.2. Distribution by Phase of Development
      • 4.6.1.3. Distribution by Indication

5. TECHNOLOGIES FOR SUBCUTANEOUS FORMULATION OF BIOLOGICS

  • 5.1. Chapter Overview
  • 5.2. Technology Profiles
    • 5.2.1. XeriJect (Xeris Pharmaceuticals)
      • 5.2.1.1. Technology Description
      • 5.2.1.2. Advantages
      • 5.2.1.3. Drugs Using this Technology
    • 5.2.2. XeriSol (Xeris Pharmaceuticals)
      • 5.2.2.1. Technology Description
      • 5.2.2.2. Advantages
      • 5.2.2.3. Developments
      • 5.2.2.4. Drugs Using this Technology
    • 5.2.3. BioChaperone (ADOCIA)
      • 5.2.3.1. Technology Description
      • 5.2.3.2. Advantages
      • 5.2.3.3. Developments
      • 5.2.3.4. Drugs Using this Technology
    • 5.2.4. High Concentration Formulation (HCF) Technology(Integrity Bio)
      • 5.2.4.1. Technology Description
      • 5.2.4.2. Advantages
    • 5.2.5. Crystalomics Technology (Ajinomoto Althea)
      • 5.2.5.1. Advantages
      • 5.2.5.2. Developments
    • 5.2.6. ENHANZE Technology (Halozyme Therapeutics)
      • 5.2.6.1. Technology Description
      • 5.2.6.2. Advantages
      • 5.2.6.3. Developments
      • 5.2.6.4. Drugs Using this Technology
    • 5.2.7. Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate Technology (Alnylam Pharmaceuticals)
      • 5.2.7.1. Advantages
      • 5.2.7.2. Developments
      • 5.2.7.3. Drugs Using this Technology
    • 5.2.8. Medusa (Flamel Technologies)
      • 5.2.8.1. Advantages
      • 5.2.8.2. Developments
      • 5.2.8.3. Drugs Using this Technology
    • 5.2.9. Controlled Release Technology (MedinCell)
      • 5.2.9.1. Advantages
      • 5.2.9.2. Drugs Using this Technology
    • 5.2.10. TransCon Technology (Ascendis Pharma)
      • 5.2.10.1. Advantages
      • 5.2.10.2. Developments
      • 5.2.10.3. Drugs Using this Technology
    • 5.2.11. Antibody Stabilization Technology (Garvan Researchers)
      • 5.2.11.1. Advantages
      • 5.2.11.2. Drugs Using this Technology
    • 5.2.12. LNP technology (Tekmira)
      • 5.2.12.1. Advantages
      • 5.2.12.2. Drugs Using this Technology

6. DRUG DELIVERY SYSTEMS FOR SUBCUTANEOUS DELIVERY OF BIOLOGICS

  • 6.1. Chapter Overview
  • 6.2. Types of Subcutaneous Delivery Systems
  • 6.3. Selection of a Suitable Delivery Device
  • 6.4. Wearable Injectors
    • 6.4.1. Types of Wearable Injectors
      • 6.4.1.1. Insulin Pumps with Infusion Sets
      • 6.4.1.2. Insulin Patch Pumps
      • 6.4.1.3. Transdermal Patch
      • 6.4.1.4. Bolus Injectors
  • 6.5. Prefilled Syringes
    • 6.5.1. Classification of Prefilled Syringes
    • 6.5.2. Prefilled Syringe Systems Available in the Market
    • 6.5.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
    • 6.5.4. Products Available in Prefilled Syringes
  • 6.6. Auto-injectors
    • 6.6.1. Pen-injectors vs. Auto-injectors
  • 6.6.2. Safety Options in Self Injectors
  • 6.7. Drug Reconstitution Delivery Systems
    • 6.7.1. Types of Drug Constitution Systems
    • 6.7.2. Drug Reconstitution Systems for Subcutaneous Delivery
    • 6.7.3. Benefits of Advanced Reconstitution Systems
  • 6.8. Needle Free Injections

7. MARKET SIZING AND FORECAST

  • 7.1. Chapter Overview
  • 7.2. Market for Subcutaneous Biologic Drugs
    • 7.2.1. Forecast Methodology
    • 7.2.2. Subcutaneous Biologics Market, 2014 - 2025
  • 7.3. Market for Drug Delivery Systems
    • 7.3.1. Prefilled Syringes for Subcutaneous Administraiton, Market Forecast, 2014 - 2025
    • 7.3.2. Large Volume Wearable Injectors for Subcutaneous Administration Market Forecast, 2014 - 2025
    • 7.3.3. Novel Drug Reconstitution Systems Market Forecast, 2014 - 2025
  • 7.4. Technology Licensing Payments

8. CASE STUDIES: TECHNOLOGY DEVELOPERS

  • 8.1. Chapter Overview
  • 8.2. Halozyme Therapeutics
    • 8.2.1. Company Overview
    • 8.2.2. Pipeline Overview
    • 8.2.3. Financial Performance
    • 8.2.4. Manufacturing/Technology
    • 8.2.5. Recent Partnerships/Developments
    • 8.2.6. Future Outlook
  • 8.3. Xeris Pharmaceuticals
    • 8.3.1. Company Overview
    • 8.3.2. Pipeline Overview
    • 8.3.3. Technology
    • 8.3.4. Recent Partnerships/Developments
    • 8.3.5. Future Outlook
  • 8.4. Integrity Bio
    • 8.4.1. Company Overview
    • 8.4.2. Technology
  • 8.5. Alnylam Pharmaceuticals
    • 8.5.1. Company Overview
    • 8.5.2. Pipeline Overview
    • 8.5.3. Financial Information
    • 8.5.4. Manufacturing/Technology
    • 8.5.5. Recent Partnerships/Developments
    • 8.5.6. Future Outlook
  • 8.6. Ajinomoto Athlea
    • 8.6.1. Company Overview
    • 8.6.2. Financial Overview
    • 8.6.3. Manufacturing/technology
    • 8.6.4. Recent Partnerships/Developments
    • 8.6.5. Future Outlook
  • 8.7. ADOCIA
    • 8.7.1. Company Overview
    • 8.7.2. Pipeline Overview
    • 8.7.3. Financial Overview
    • 8.7.4. Manufacturing/ Technology
    • 8.7.5. Recent Developments/Partnerships
    • 8.7.6. Future Outlook
  • 8.8. Flamel Technologies
    • 8.8.1. Company Overview
    • 8.8.2. Pipeline Overview
    • 8.8.3. Financial Overview
    • 8.8.4. Manufacturing/Technology
    • 8.8.5. Recent Partnerships/Developments
    • 8.8.6. Future Outlook
  • 8.9. MedinCell
    • 8.9.1. Company Overview
    • 8.9.2. Manufacturing/Technology
    • 8.9.3. Recent Partnerships/Developments
    • 8.9.4. Future Outlook
  • 8.10. Ascendis Pharma
    • 8.10.1. Company Overview
    • 8.10.2. Manufacturing/Technology
    • 8.10.3. Partnerships
    • 8.10.4. Future Outlook

9. SWOT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Strengths
  • 9.3. Weaknesses
  • 9.4. Opportunities
  • 9.5. Threats

10. INTERVIEW TRANSCRIPTS

11. CONCLUSION

  • 11.1. Transition from Intravenous to Subcutaneous: A Powerful Concept
  • 11.2. Multiple Drivers to Fuel the Growth
  • 11.3. A Multi-Billion Dollar Rapidly Growing Market
  • 11.4. A Whole New Set of Opportunities for Multiple Stakeholders

12 APPENDIX 1: TABULATED DATA

13 APPENDIX 2: LIST OF COMPANIES

List of Figures:

  • Figure 4.1: Numbers of Biologics Approved by the USFDA, 2009-2013
  • Figure 4.2: Leading Subcutaneous Biologics By Sales, 2013 (USD Million)
  • Figure 4.3: HER2 Expression in Breast Cancer Patients (%)
  • Figure 4.4: Herceptin Sales, 1999 - 2013 (CHF Billion)
  • Figure 4.5: MabThera: Target Population for Follicular Non-Hodgkin's Lymphoma)
  • Figure 4.6: MabThera: Target Population for Diffuse Large B-cell Non-Hodgkin's Lymphoma
  • Figure 4.7: MabThera: Target Population for Chronic Lymphocytic Leukemia
  • Figure 4.8: Rituximab Sales, 1999 - 2013 (CHF Billion)
  • Figure 4.9: Neulasta Sales, 2003 - 2013 (USD Billion)
  • Figure 4.10: Humira Global Sales, 2003-2013 (USD Billion)
  • Figure 4.11: Enbrel US Sales, 2002-2013 (USD Million)
  • Figure 4.12: Subcutaneous Biologics Pipeline: Distribution by Type of Molecule
  • Figure 4.13: Subcutaneous Biologics Pipeline: Distribution by Phase of Development
  • Figure 4.14: Subcutaneous Biologics Pipeline: Leading Indications/ Therapeutic Areas
  • Figure 5.1: XeriJect Technology: Process
  • Figure 5.2: Medusa Formulation Technology: Process
  • Figure 5.3: Controlled Release Technology: Process
  • Figure 6.1: Subcutaneous Drug Delivery Systems: Injection Volume Range
  • Figure 6.2: Benefits of Large Volume Wearable Injectors to Stakeholders
  • Figure 6.3: Prefilled Syringes: Market Landscape by Manufacturer
  • Figure 7.1: Subcutaneous Biologics Market, 2014 - 2025: Base Scenario (USD Billion)
  • Figure 7.2: Global Prefilled Syringes, Forecast Number of Units, 2014 - 2025 (Billions)
  • Figure 7.3: Global Prefilled Syringes, Sales Forecast, 2014 - 2025 (USD Billion)
  • Figure 7.4: Overall Large Volume Wearable Injectors Market (Number of Devices, Millions), 2014 - 2025
  • Figure 7.5: Overall Large Volume Wearable Injectors Market (USD Million), 2014 - 2025
  • Figure 7.6: Novel Drug Reconstitution Systems Market for Subcutaneous Administration, 2014-2025
  • Figure 7.7: Upfront Payments: Scatter Plot Representation
  • Figure 7.8: Milestone Payments: Scatter Plot Representation
  • Figure 8.1: Pipeline: Halozyme Therapeutics
  • Figure 8.2: Halozyme Therapeutics: Revenues, 2009 - 2013 (USD Million)
  • Figure 8.3: Halozyme Therapeutics: Revenues by Business Divisions, FY 2013 (USDMillion)
  • Figure 8.4: Pipeline: Xeris Pharmaceuticals
  • Figure 8.5: Pipeline: Alnylam Pharmaceuticals
  • Figure 8.6: Alnylam Pharmaceuticals: Revenues, 2009-2013 (USD Million)
  • Figure 8.7: Alnylam Pharmaceuticals: Net Revenues from Collaborators, FY 2013 (USD Million)
  • Figure 8.8: Ajinomoto Co: Revenues, 2009-2013 (JPY Billion)
  • Figure 8.9: Ajinomoto Co: Revenues by Business Segments, FY 2014 (JPY Billion)
  • Figure 8.10: Pipeline: ADOCIA
  • Figure 8.11: ADOCIA: Revenues, 2011-2013 (EUR Million)
  • Figure 8.12: ADOCIA: Revenues by Business Segments, FY 2013 (EUR Million)
  • Figure 8.13: Pipeline: Flamel Technologies
  • Figure 8.14: Flamel Technologies: Annual Revenue, 2009-2013 (USD Million)
  • Figure 8.15: Flamel Technologies: Distribution of Annual Revenue by Operating Region, FY 2013 (USD' 000)
  • Figure 11.1: Subcutaneous Biologics Market (USD Billion): Comparative Scenarios, 2014, 2019 and 2025

List of Tables:

  • Table 3.1: Biotherapeutics: Physical and Chemical Instabilities
  • Table 4.1: List of Marketed Subcutaneous Biologics
  • Table 4.2: Subcutaneous vs. Intravenous Herceptin
  • Table 4.3: Subcutaneous vs. Intravenous Rituximab
  • Table 4.4: List of Pipeline Subcutaneous Biologics
  • Table 5.1: Technologies for Subcutaneous Delivery of Biologics
  • Table 5.2: Drugs Using the Xerisol Technology
  • Table 5.3: Drugs using BioChaperone Technology
  • Table 5.4: Drugs Using the Enhanze Technology
  • Table 5.5: Drugs Using the (ESC)-GalNAc-conjugate Technology
  • Table 5.6: Drugs Using Medusa Technology
  • Table 5.7: Pipeline Products Using TransCon Technology
  • Table 6.1: Large Volume Wearable Injectors under Development
  • Table 6.2: Large Volume Wearable Injectors: Benefits v/s Perceived Issues
  • Table 6.3: Classification of Prefilled Syringes
  • Table 6.4: Prefilled Syringe Systems Available in the Market, 2014: A Comparison, By Manufacturer
  • Table 6.5: Drugs Approved in Prefilled Syringes, 2013-2014
  • Table 6.6: Auto-injector/Pen-injector Systems Approved in 2013-2014
  • Table 6.7: Auto-injector/Pen-injector Systems (Using Prefilled Syringes) Available in the Market
  • Table 6.8: Drug Reconstitution Systems for Subcutaneous Administration
  • Table 6.9: List of Needleless Injection Systems
  • Table 7.1: Technology Licensing Deals
  • Table 8.1: Ajinomoto Althea: Medium Term Management Plan
  • Table 8.2: ADOCIA: Short-term Plans for Pipeline Products
  • Table 9.1: SWOT Analysis
  • Table 9.2: Recall of Auto-injectors
  • Table 9.3: Prefilled Syringe Recalls, 2003-2014
  • Table 12.1: Leading Subcutaneous Biologics by Sales, 2013 (USD Million)
  • Table 12.2: Herceptin Sales, 1999 - 2013 (CHF Billion)
  • Table 12.3: MabThera Sales, 1999 - 2013 (CHF Billion)
  • Table 12.4: Neulasta Sales, 2002 - 2013 (USD Billion)
  • Table 12.5: Humira Global Sales, 2004-2013 (USD Billion)
  • Table 12.6: Enbrel Global Sales, 2002-2013 (USD Billion)
  • Table 12.7: Subcutaneous Biologics Pipeline: Distribution by Type of Molecule
  • Table 12.8: Subcutaneous Biologics Pipeline: Distribution by Phase of Development
  • Table 12.9: Subcutaneous Biologics Pipeline: Leading Indications/ Therapeutic Areas
  • Table 12.10: Halozyme Therapeutics, Revenues: 2009 - 2013 (USD Million)
  • Table 12.11: Halozyme Therapeutics, Revenues by Business Divisions: 2013 (USD Million)
  • Table 12.12: Alnylam Pharmaceuticals: Revenues, 2009-2013 (USD Million)
  • Table 12.13: Alnylam Pharmaceuticals: Net Revenues from Collaborators, 2013 (USD Million)
  • Table 12.14: Ajinomoto Co., Inc.: Annual Revenue 2009-2013 (in JPY million)
  • Table 12.15: Ajinomoto Co., Inc.: Distribution of Revenue by Operating Segments 2014
  • Table 12.16: ADOCIA: Revenues, 2011-2013 (EUR Million)
  • Table 12.17: ADOCIA: Distribution of Revenues by Operating Segments, 2013
  • Table 12.18: Flamel Technologies: Annual Revenue 2009-2013 (USD Million)
  • Table 12.19: Subcutaneous Biologics Market, 2014 - 2025: Base Scenario (USD Billion)
  • Table 12.20: Subcutaneous Biologics Market, 2014 - 2025: Conservative Scenario (USD Billion)
  • Table 12.21: Subcutaneous Biologics Market, 2014 - 2025: Optimistic Scenario (USD Billion)
  • Table 12.22: Global Prefilled Syringes for Subcutaneous Biologics, Forecast Number of Units, 2014 - 2025 (Billions)
  • Table 12.23: Global Prefilled Syringes, Sales Forecast, 2014 - 2025 (USD Billion)
  • Table 12.24: Overall Large Volume Wearable Injectors Market (Number of Devices, Millions), 2014 - 2025
  • Table 12.25: Overall Large Volume Wearable Injectors Market (USD Million), 2014 - 2025
  • Table 12.26: Novel Drug Reconstitution Systems Market for Subcutaneous Administration (USD Billion), 2014-2025

List of Companies:

The following companies have been mentioned in this report.

  • 1. Abbott Laboratories
  • 2. Activa
  • 3. Adamis Pharmaceuticals Corporation
  • 4. ADOCIA
  • 5. Advantage Health Services
  • 6. Aguettant
  • 7. Ajinomoto Althea Inc.
  • 8. Alnylam Pharmaceuticals
  • 9. Amgen
  • 10. Antares Pharma
  • 11. Aptar Pharm
  • 12. Aradigm Corporation
  • 13. Arte Corporation
  • 14. Ascendis Pharma
  • 15. AstraZeneca
  • 16. Bang and Olufsen
  • 17. Battelle
  • 18. Baxter
  • 19. Bayer
  • 20. Becton Dickinson
  • 21. Bespak
  • 22. Biogen Idec
  • 23. Bioject Medical Technologies, Inc.
  • 24. Bristol-Myers Squibb Co
  • 25. Calibra Medical
  • 26. CeQur SA
  • 27. Chengdu Instituteof Biologic Products, Biogenetech
  • 28. CNS Therapeutics (acquired by Mallinckrodt)
  • 29. CSL Behring
  • 30. Duoject
  • 31. Eagle Pharmaceuticals
  • 32. Elcam Medical
  • 33. Eli Lilly
  • 34. EMD Serono
  • 35. Emergent Biosolutions
  • 36. Enable Injections
  • 37. Eternity Healthcare
  • 38. Evans enterprise
  • 39. Flamel Technologies
  • 40. Future injection technologies
  • 41. Genzyme
  • 42. Gerresheimer
  • 43. Grifols Therapeutics (acquired Talecris Biotherapeutics)
  • 44. GSK
  • 45. Halozyme
  • 46. Haselmeier
  • 47. Health for personal Care
  • 48. Injex - Equidyne Systems
  • 49. Integrity Bio
  • 50. Janssen Biotech, Inc.
  • 51. Kaleo Inc.
  • 52. Mediject
  • 53. MedinCell
  • 54. MedPro
  • 55. Merck
  • 56. Meridian
  • 57. National Medical Products, Inc.
  • 58. Nipro (acquired MGlas AG)
  • 59. NouvaOmpi
  • 60. Novartis
  • 61. Novo Nordisk
  • 62. Owen Mumford
  • 63. PA Consulting
  • 64. Penjet corporation
  • 65. Pfizer
  • 66. Plas-Tech Engineering
  • 67. Ratio Inc.
  • 68. Roche
  • 69. Roselabs Bioscience
  • 70. Sanofi
  • 71. Scandinavian Health Limited (SHL Medical)
  • 72. Schering Corporation (Merck Serono)
  • 73. Schott
  • 74. Sensile Medical
  • 75. Shandong Weigao
  • 76. Sobi
  • 77. SteadyMed
  • 78. Taisei Kako
  • 79. Tekmira
  • 80. Terumo Corporation
  • 81. The Medical House
  • 82. UCB
  • 83. Unilife Corporation
  • 84. United Therapeutics
  • 85. Valeritas
  • 86. Vetter Pharma
  • 87. West Pharmaceutical Solutions
  • 88. Xeris Pharmaceuticals
  • 89. Ypsomed
Back to Top